Carmen Rubio1, Rosa Morera2, Ovidio Hernando1, Thomas Leroy3, S Eric Lartigau3. 1. Academic Radiation Oncology Department, HM Universitario Sanchinarro, Madrid, Spain. 2. Radiation Oncology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain. 3. Academic Radiotherapy Department, Centre Oscar Lambret, University of Lille II-Nord de France, Lille, France.
Abstract
AIM: Review of main SBRT features and indications in primary tumors. BACKGROUND: Stereotactic body radiotherapy has been developed in the last few years. SBRT allows the hypofractionated treatment of extra cranial tumors, using either a single or limited number of dose fractions, and resulting in the delivery of a high biological effective dose with low toxicity. MATERIAL AND METHODS: SBRT REQUIRES A HIGH LEVEL OF ACCURACY FOR ALL PHASES OF THE TREATMENT PROCESS: effective patient immobilization, precise target localization, highly conformed dosimetry and image guided systems for treatment verification. The implementation of SBRT in routine requires a careful considering of organ motion. Gating and tracking are effective ways to do so, and less invasive technologies "fiducials free" have been developed. Due to the hypofractionated scheme, the physician must pay attention to new dosimetric constraints in organ at risk and new radiobiological models are needed to assess the optimal fractionation and dose schemes. RESULTS: Currently, SBRT is safe and effective to treat primary tumors, which are otherwise untreatable with conventional radiotherapy or surgery. SBRT has quickly developed because of its excellent results in terms of tolerance and its high locoregional control rates. SBRT indications in primary tumors, such as lung primary tumors, have become a standard of care for inoperable patients. SBRT seems to be effective in many others indications in curative or palliative intent such as liver primary tumors, and novel indications and strategies are currently emerging in prostate cancer, head and neck tumor recurrences or pelvis reirradiations. CONCLUSION: Currently, SBRT is mainly used when there is no other therapeutic alternative for the patient. This is due to the lack of randomized trials in these settings. However, the results shown in retrospective studies let us hope to impose SBRT as a new standard of care for many patients in the next few years.
AIM: Review of main SBRT features and indications in primary tumors. BACKGROUND: Stereotactic body radiotherapy has been developed in the last few years. SBRT allows the hypofractionated treatment of extra cranial tumors, using either a single or limited number of dose fractions, and resulting in the delivery of a high biological effective dose with low toxicity. MATERIAL AND METHODS: SBRT REQUIRES A HIGH LEVEL OF ACCURACY FOR ALL PHASES OF THE TREATMENT PROCESS: effective patient immobilization, precise target localization, highly conformed dosimetry and image guided systems for treatment verification. The implementation of SBRT in routine requires a careful considering of organ motion. Gating and tracking are effective ways to do so, and less invasive technologies "fiducials free" have been developed. Due to the hypofractionated scheme, the physician must pay attention to new dosimetric constraints in organ at risk and new radiobiological models are needed to assess the optimal fractionation and dose schemes. RESULTS: Currently, SBRT is safe and effective to treat primary tumors, which are otherwise untreatable with conventional radiotherapy or surgery. SBRT has quickly developed because of its excellent results in terms of tolerance and its high locoregional control rates. SBRT indications in primary tumors, such as lung primary tumors, have become a standard of care for inoperable patients. SBRT seems to be effective in many others indications in curative or palliative intent such as liver primary tumors, and novel indications and strategies are currently emerging in prostate cancer, head and neck tumor recurrences or pelvis reirradiations. CONCLUSION: Currently, SBRT is mainly used when there is no other therapeutic alternative for the patient. This is due to the lack of randomized trials in these settings. However, the results shown in retrospective studies let us hope to impose SBRT as a new standard of care for many patients in the next few years.
Entities:
Keywords:
Early stage NCSLC; Head and neck recurrences; Hepatocellular carcinoma; Organ motion; Requirements; SBRT
Authors: Dirk Verellen; Guy Soete; Nadine Linthout; Swana Van Acker; Patsy De Roover; Vincent Vinh-Hung; Jan Van de Steene; Guy Storme Journal: Radiother Oncol Date: 2003-04 Impact factor: 6.280
Authors: Ronald C McGarry; Lech Papiez; Mark Williams; Tia Whitford; Robert D Timmerman Journal: Int J Radiat Oncol Biol Phys Date: 2005-08-22 Impact factor: 7.038
Authors: Louis Potters; Michael Steinberg; Christopher Rose; Robert Timmerman; Samuel Ryu; James M Hevezi; James Welsh; Minesh Mehta; David A Larson; Nora A Janjan Journal: Int J Radiat Oncol Biol Phys Date: 2004-11-15 Impact factor: 7.038
Authors: Byung Ock Choi; Hong Seok Jang; Ki Mun Kang; Sang Wook Lee; Young Nam Kang; Gyu Young Chai; Ihl Bhong Choi Journal: Jpn J Clin Oncol Date: 2006-03-06 Impact factor: 3.019
Authors: Frank B Zimmermann; Hans Geinitz; Sabine Schill; Anca Grosu; Ulrich Schratzenstaller; Michael Molls; Branislav Jeremic Journal: Lung Cancer Date: 2004-12-19 Impact factor: 5.705
Authors: Carmen Rubio; Ovidio Hernando-Requejo; Daniel Zucca Aparicio; María ALlona Krauel; Mercedes López Gonzalez; Juan María Pérez; Emilio Sánchez Saugar; Pedro Fernández Letón Journal: Rep Pract Oncol Radiother Date: 2016-09-17
Authors: Lindsay Hwang; Christian C Okoye; Ravi B Patel; Arjun Sahgal; Matthew Foote; Kristin J Redmond; Christoph Hofstetter; Rajiv Saigal; Mahmud Mossa-Basha; William Yuh; Nina A Mayr; Samuel T Chao; Eric L Chang; Simon S Lo Journal: J Radiosurg SBRT Date: 2019